Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Muraglitazar
Cat. No.:
0225LY-0829
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Muraglitazar is a dual PPAR-alpha/gamma agonist used to treat type 2 diabetes and dyslipidemia, with human EC50 values of 320 nM and 110 nM, respectively.
Synonym:
Pargluva; BMS-298585; 331741-94-7; 2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid; MK0478; MK-0478; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; 2-(((4-methoxyphenoxy)carbonyl)(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid; Glycine, N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-
CAS No.:
331741-94-7
Compound CID:
206044
Formula:
C29H28N2O7
Formula Weight:
516.54
Specification
Relative Density:
1.274 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Muraglitazar can be used in metabolic research to examine the synergistic effects of dual PPAR alpha/gamma activation.
Library Information
Target:
PPAR
Receptor:
PPARα ; PPARγ
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-11
Plate Location:
f8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
128.8 mg/mL; 249.35 mM
